Cargando…

Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study

BACKGROUND: Ketamine and its enantiomer esketamine represent promising new treatments for treatment-resistant depression (TRD). Esketamine induces acute, transient psychoactive effects. How patients perceive esketamine treatment, and which conditions facilitate optimal outcomes, remains poorly under...

Descripción completa

Detalles Bibliográficos
Autores principales: Breeksema, Joost J., Niemeijer, Alistair, Kuin, Bouwe, Veraart, Jolien, Kamphuis, Jeanine, Schimmel, Nina, van den Brink, Wim, Vermetten, Eric, Schoevers, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732097/
https://www.ncbi.nlm.nih.gov/pubmed/36506427
http://dx.doi.org/10.3389/fpsyt.2022.948115
_version_ 1784846054304251904
author Breeksema, Joost J.
Niemeijer, Alistair
Kuin, Bouwe
Veraart, Jolien
Kamphuis, Jeanine
Schimmel, Nina
van den Brink, Wim
Vermetten, Eric
Schoevers, Robert
author_facet Breeksema, Joost J.
Niemeijer, Alistair
Kuin, Bouwe
Veraart, Jolien
Kamphuis, Jeanine
Schimmel, Nina
van den Brink, Wim
Vermetten, Eric
Schoevers, Robert
author_sort Breeksema, Joost J.
collection PubMed
description BACKGROUND: Ketamine and its enantiomer esketamine represent promising new treatments for treatment-resistant depression (TRD). Esketamine induces acute, transient psychoactive effects. How patients perceive esketamine treatment, and which conditions facilitate optimal outcomes, remains poorly understood. Understanding patient perspectives on these phenomena is important to identify unmet needs, which can be used to improve (es)ketamine treatments. AIMS: To explore the perspectives of TRD patients participating in “off label” oral esketamine treatment. MATERIALS AND METHODS: In-depth interviews were conducted with 17 patients (11 women) after a six-week, twice-weekly esketamine treatment program, and subsequently after six months of at-home use. Interviews explored participants’ perspectives, expectations, and experiences with esketamine treatment. Audio interviews were transcribed verbatim and analysed following an Interpretative Phenomenological Analysis (IPA) framework. RESULTS: Key themes included overwhelming experiences; inadequate preparation; letting go of control; mood states influencing session experiences; presence and emotional support, and supportive settings. Patients’ attempts to let go and give into vs. attempts to maintain control over occasionally overwhelming experiences was a central theme. Multiple factors influenced patients’ ability to give into the experience and appeared to impact their mood and anxiety about future sessions, including level of preparation and education, physical and emotional support, and setting during the session. CONCLUSION: Better preparation beforehand, an optimized treatment setting, and emotional and psychological support during (es)ketamine sessions can help patients to “let go” and may lead to better quality of care and outcomes. Recommendations to improve quality of patient care in (es)ketamine treatment are provided, including suggestions for the training of nurses and other support staff.
format Online
Article
Text
id pubmed-9732097
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97320972022-12-10 Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study Breeksema, Joost J. Niemeijer, Alistair Kuin, Bouwe Veraart, Jolien Kamphuis, Jeanine Schimmel, Nina van den Brink, Wim Vermetten, Eric Schoevers, Robert Front Psychiatry Psychiatry BACKGROUND: Ketamine and its enantiomer esketamine represent promising new treatments for treatment-resistant depression (TRD). Esketamine induces acute, transient psychoactive effects. How patients perceive esketamine treatment, and which conditions facilitate optimal outcomes, remains poorly understood. Understanding patient perspectives on these phenomena is important to identify unmet needs, which can be used to improve (es)ketamine treatments. AIMS: To explore the perspectives of TRD patients participating in “off label” oral esketamine treatment. MATERIALS AND METHODS: In-depth interviews were conducted with 17 patients (11 women) after a six-week, twice-weekly esketamine treatment program, and subsequently after six months of at-home use. Interviews explored participants’ perspectives, expectations, and experiences with esketamine treatment. Audio interviews were transcribed verbatim and analysed following an Interpretative Phenomenological Analysis (IPA) framework. RESULTS: Key themes included overwhelming experiences; inadequate preparation; letting go of control; mood states influencing session experiences; presence and emotional support, and supportive settings. Patients’ attempts to let go and give into vs. attempts to maintain control over occasionally overwhelming experiences was a central theme. Multiple factors influenced patients’ ability to give into the experience and appeared to impact their mood and anxiety about future sessions, including level of preparation and education, physical and emotional support, and setting during the session. CONCLUSION: Better preparation beforehand, an optimized treatment setting, and emotional and psychological support during (es)ketamine sessions can help patients to “let go” and may lead to better quality of care and outcomes. Recommendations to improve quality of patient care in (es)ketamine treatment are provided, including suggestions for the training of nurses and other support staff. Frontiers Media S.A. 2022-11-25 /pmc/articles/PMC9732097/ /pubmed/36506427 http://dx.doi.org/10.3389/fpsyt.2022.948115 Text en Copyright © 2022 Breeksema, Niemeijer, Kuin, Veraart, Kamphuis, Schimmel, van den Brink, Vermetten and Schoevers. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Breeksema, Joost J.
Niemeijer, Alistair
Kuin, Bouwe
Veraart, Jolien
Kamphuis, Jeanine
Schimmel, Nina
van den Brink, Wim
Vermetten, Eric
Schoevers, Robert
Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study
title Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study
title_full Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study
title_fullStr Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study
title_full_unstemmed Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study
title_short Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study
title_sort holding on or letting go? patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: a qualitative study
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732097/
https://www.ncbi.nlm.nih.gov/pubmed/36506427
http://dx.doi.org/10.3389/fpsyt.2022.948115
work_keys_str_mv AT breeksemajoostj holdingonorlettinggopatientexperiencesofcontrolcontextandcareinoralesketaminetreatmentfortreatmentresistantdepressionaqualitativestudy
AT niemeijeralistair holdingonorlettinggopatientexperiencesofcontrolcontextandcareinoralesketaminetreatmentfortreatmentresistantdepressionaqualitativestudy
AT kuinbouwe holdingonorlettinggopatientexperiencesofcontrolcontextandcareinoralesketaminetreatmentfortreatmentresistantdepressionaqualitativestudy
AT veraartjolien holdingonorlettinggopatientexperiencesofcontrolcontextandcareinoralesketaminetreatmentfortreatmentresistantdepressionaqualitativestudy
AT kamphuisjeanine holdingonorlettinggopatientexperiencesofcontrolcontextandcareinoralesketaminetreatmentfortreatmentresistantdepressionaqualitativestudy
AT schimmelnina holdingonorlettinggopatientexperiencesofcontrolcontextandcareinoralesketaminetreatmentfortreatmentresistantdepressionaqualitativestudy
AT vandenbrinkwim holdingonorlettinggopatientexperiencesofcontrolcontextandcareinoralesketaminetreatmentfortreatmentresistantdepressionaqualitativestudy
AT vermetteneric holdingonorlettinggopatientexperiencesofcontrolcontextandcareinoralesketaminetreatmentfortreatmentresistantdepressionaqualitativestudy
AT schoeversrobert holdingonorlettinggopatientexperiencesofcontrolcontextandcareinoralesketaminetreatmentfortreatmentresistantdepressionaqualitativestudy